FOLH1 and prostate cancer: Fully mesyl or mixed mesyl (gap) and busyl (wings) all-deoxy ASOs (md and bmd, respectively) were conjugated with two variants of the previously validated PSMA ligands, namely, MA-257 and MA-415 (Machulkin et al., 2019; Machulkin et al., 2021) for targeted delivery to prostate cancer cells.